Chemours Company (the) · NYSE:CC
Chemours Company (the) — Q3 2025 Earnings Presentation
26 slides from Chemours Company (the)'s earnings presentation, Nov 7, 2025
Slide 1: The Chemours Company Q3 2025 Earnings Presentation
THE CHEMOURS COMPANY Q3 2025 EARNINGS PRESENTATION November 7, 2025
Slide 2: Safe Harbor Statement and Other Matters
Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current exp
Slide 3: Third Quarter 2025 Highlights
Third Quarter 2025 Highlights Generated $1.5B in Net Sales and $195M in Adjusted EBITDA Achieved 80% YoY Net Sales growth for Opteon Refrigerants in TSS, reflecting continued strong adoption Announced the successful qualification of Chemours’ two-phase immersion cooling fluid by Samsung Electronics
Slide 4: Third Quarter 2025 Financial Summary
Third Quarter 2025 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) 3Q25 3Q24 5 Y-o-Y ∆ 2Q25 Q-o-Q ∆ Net Sales $1,495 $1,508 ($13) $1,615 ($120) Net Income / (Loss) 1 $60 ($32) $92 ($381) $441 Adj. Net Income 2 $30 $61 ($31) $87 ($57) EPS 3 $0.40 ($0.22) $0.62 ($2
Slide 5: Adjusted EBITDA Bridge: 3Q25 versus 3Q24
Adjusted EBITDA Bridge: 3Q25 versus 3Q24 ($ in millions) $18 $7 ($47) $15 $202 $195 5 3Q24 Price Volume Cost/Other Currency 3Q25 Price Impacts: $7 million due to higher pricing in TSS primarily driven by stronger Opteon Refrigerant blends aftermarket demand and strong pricing in APM, in connection w
Slide 6: Quarterly Segment Summary
Quarterly Segment Summary ($ in millions unless otherwise noted) Net Sales 5 TSS TT APM $436 $468 $560 $690 $672 $612 $343 $354 $311 3Q23 3Q24 3Q25 3Q23 3Q24 3Q25 3Q23 3Q24 3Q25 Adjusted EBITDA and Margin 5 (%) TSS TT APM $25 $14 $162 $139 $194 $69 $78 $68 $38 3Q23 3Q24 3Q25 3Q23 3Q24 3Q25 3Q23 3Q24
Slide 7: Liquidity Position as of September 30, 2025
Liquidity Position as of September 30, 2025 ($ in millions unless otherwise noted) Total Liquidity 9 $1.6B Gross Debt $4.2B Net Debt 10 $3.6B TTM Net Leverage 11 4.6x $665 $52 Restricted $553 ($41) ($13) $20 $51 Restricted $146 $502 $613 Unrestricted Unrestricted 2Q25 Cash Balance 6 Operating Cash F
Slide 8: Strategic Progress
STRATEGIC PROGRESS PATHWAY TO THRIVE
Slide 9: Our Strategy
Our Strategy PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long-Term ❑Manufacturing excellence as ❑Investing smartly in selected ❑Holistic portfolio analysis ❑Measurable progress on a basis for success growth projects focused on distinct value resolv
Slide 10: Progress Achieved to Date
Progress Achieved to Date PATHWAY TO THRIVE Operational Enabling Portfolio Strengthening Excellence Growth Management the Long-Term ✓ On track to deliver ~$125M of ✓ Continued double-digit growth with ✓ Strategic agreement with SRF ✓ Agreed to a proposed Judicial gross cost savings within 80% YoY qu
Slide 11: 2024 Sustainability Report Highlights
2024 Sustainability Report Highlights Reduced total process FOC emissions 76%*—on our way to a 99% or more reduction by 2030 Achieved 52%* reduction of operational GHG emissions—on track to meet our 60% reduction by 2030 Accomplished the 2030 Sustainable Offerings goal 6 years early; 50% of revenue
Slide 12: Q4 and Full Year
SB O4 AND Gao}! FULL YEAR 1°,
Slide 13: Fourth Quarter 2025 Guidance
Fourth Quarter 2025 Guidance Sequential Business Outlook: Consolidated o Net Sales: Expected to decrease 10-15% sequentially Full Year 2025 Outlook o Adjusted EBITDA: Expected to range between $130 million and $160 million o Corporate Expenses as an offset to Adjusted EBITDA: Expected to range bet
Slide 14: Appendix
APPENDIX 14
Slide 15: TSS Segment Net Sales and Adjusted EBITDA
TSS Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) % of total Net Sales $560 $468 FP&O $35 17% FP&O $57 Freon 25% Refrigerants Freon 17% Refrigerants Q3 24 % total Q3 25 % total 31% refrigerants: refrigerants: Freon = 42% Freon = 20% Opteon = 58% Opteon = 80% Opte
Slide 16: TT Segment Net Sales and Adjusted EBITDA
TT Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) $672 $612 ($43) ($17) $78 $25 3Q24 Price/Currency Volume 3Q25 3Q24 Price/Currency Volume Cost/Other 3Q25 Net Sales: The year-over-year decrease was primarily driven by an 8% decrease in price globally, partially of
Slide 17: APM Segment Net Sales and Adjusted EBITDA
APM Segment Net Sales and Adjusted EBITDA (Unaudited)5 ($ in millions) ($ in millions) % of total Net Sales $354 $311 Performance $11 Solutions ($54) Performance 40% Solutions 39% Advanced Advanced Materials Materials 60% 61% $38 $14 3Q24 Price/Currency Volume 3Q25 3Q24 Price/Currency Volume Cost/Ot
Slide 18: Segment Net Sales
Segment Net Sales (Unaudited)5 18 Chemours - Internal Use Only
Slide 19: Segment Net Sales by Region
Segment Net Sales by Region (Unaudited)5 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Net sales by geographic region North America: Thermal & Specialized Solutions $ 292 $ 319 $ 258 $ 207 $ 271 $ 308 $ 256 $ 194 $ 233 $ 336 $ 316 Titanium Technologies 262 277 273 242 246 274 270 236 267 282 252 A
Slide 20: Actual and Projected Disruption & Investment Costs
Actual and Projected Disruption & Investment Costs (Unaudited) 2024 2025 ($, millions) Q1 - Act Q2 - Act Q3 - Act Q4 - Act Total Q1 - Act Q2 - Act Q3 - Act Q4 - Guide Total Disruption Costs Thermal & Specialized Solutions (TSS) Winter Storm $ - $ - $ - $ - $ - $ 5 $ - $ - $ - $ 5 Titanium Technologi
Slide 21: Segment Net Sales and Adjusted EBITDA
Segment Net Sales and Adjusted EBITDA (Unaudited)5 2023 2024 2025 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Segment Net Sales Thermal & Specialized Solutions $ 494 $ 533 $ 444 $ 380 $ 454 $ 519 $ 468 $ 390 $ 466 $ 597 $ 560 Titanium Technologies 632 707 690 651 591 677 672 632 597 657 612 Advanced Performanc
Slide 22: GAAP Net Income to Adjusted Net Income and EBITDA
GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 1/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended September 30, Ju
Slide 23: GAAP Net Income to Adjusted Net Income and EBITDA
GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio5 (Page 2/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Twelve Months Ended September 30, Ju
Slide 24: GAAP Cash Flow to Free Cash Flow
GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation ($ in millions) Three Months Ended Nine Months Ended September 30, June 30, September 30, 2025 2024 2025 2025 2024 Cash flows provided by (used for) operating activities $ 146 $ 139 $ 93 $
Slide 25: 2025 Estimated GAAP Net Income to Adjusted EBITDA
2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA(*) (In millions except per share amounts) (Estimated) Year Ending December 31, 2025 Low High Net loss attributable to Chemours $ (335) $ (318) Restructuring, transaction, and other cos
Slide 26: 2025 Chemours. All Rights Reserved
® 2025 CHEMOURS. ALL RIGHTS RESERVED
Chemours Company (The) — Q3 2025 Earnings Presentation on 6ix